A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Inclusion Criteria: * Confirmed diagnosis of Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Small Lymphocytic Lymphoma (SLL) * Adequate organ system function ( Absolute neutrophil count, Platelets,Bilirubin, Platelets, Aspartate transferase ,Alanine aminotransferase, Creatinine Clearance) * Eastern Cooperative Group (ECOG) Performance status ≤ 2 * Ability to swallow and retain oral medication * Female patients: must have negative serum pregnancy test at study screening/ all male partners must consent to use a medically acceptable method of contraception * Willingness and ability to comply with trial and follow-up procedures, and give written informed consent Exclusion Criteria:- * Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) within 3 weeks of Cycle 1/Day 1, * Autologous hematologic stem cell transplant within 3 months of study entry. * Allogeneic hematologic stem cell transplant within 12 months. * Post-allo patients must not have active graft versus-host disease * Evidence of active Hepatitis B,Hepatitis C or HIV infection. * Active central nervous system involvement by lymphoma * Requires treatment with strong CYP3A4/5 inhibitors * Severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study * QTcF \>470 msec (QT interval, Fredericia calculation) * Angina not well-controlled by me…